Short- and Long-Term Outcomes of Mirikizumab for Ulcerative Colitis: A Real-World Multicenter Retrospective Cohort Study from the INSIGHT study - PubMed
3 hours ago
- #real-world study
- #mirikizumab
- #ulcerative colitis
- Mirikizumab (MIR), an IL-23p19 inhibitor, showed efficacy in treating ulcerative colitis (UC) in clinical trials.
- A real-world study of 85 UC patients in Japan found clinical remission rates of 62.4% at week 12 and 55.3% at week 52.
- CS-free remission rates matched overall remission rates at both 12 and 52 weeks.
- Effectiveness was maintained regardless of prior exposure to biologics or JAK inhibitors.
- Early clinical response at week 4 predicted remission at week 52, while steroid dependence predicted week 12 remission.
- 27.3% of initial nonresponders achieved remission by week 24 with extended induction.
- Treatment was well tolerated, with 17.6% experiencing adverse events and 9.4% discontinuing due to adverse events.
- No serious infections or hospitalizations were reported.